Simon Read, Curie Therapeutics CEO

Look­ing to run with Big Phar­ma, a ra­dio­phar­ma start­up with back­ing from At­las, RA thinks it has the chops to com­pete

Amid a re­nais­sance in the field of ra­dio­phar­ma­ceu­ti­cals, a grow­ing cho­rus of bio­phar­ma play­ers is rush­ing the stage to cap­i­tal­ize on tech break­throughs. Biotech blue-chip­pers RA Cap­i­tal and At­las Ven­ture, sens­ing an op­por­tu­ni­ty, are now set­ting up their own start­up to chal­lenge the big boys.

Curie Ther­a­peu­tics un­cloaked from stealth Wednes­day with $75 mil­lion in Se­ries A fund­ing from At­las, RA and Ac­cess Biotech­nol­o­gy, with the goal of lever­ag­ing a sea­soned team of ex­perts to get the jump on the grow­ing class of can­cer ther­a­peu­tics, the biotech said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.